Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PANACEA BIOTECH Mar-19 |
ADCOCK INGRAM Jun-14 |
PANACEA BIOTECH/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 354 | 344 | - | |
Low | Rs | 138 | 248 | - | |
Sales per share (Unadj.) | Rs | 74.6 | 102.4 | - | |
Earnings per share (Unadj.) | Rs | 6.7 | -25.8 | - | |
Cash flow per share (Unadj.) | Rs | 15.5 | -21.4 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Dividend yield (eoy) | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 57.2 | 80.4 | - | |
Shares outstanding (eoy) | m | 61.25 | 168.78 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 3.3 | 2.9 | 114.0% | |
Avg P/E ratio | x | 36.8 | -11.5 | -320.6% | |
P/CF ratio (eoy) | x | 15.9 | -13.9 | -114.5% | |
Price / Book Value ratio | x | 4.3 | 3.7 | 116.6% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 15,061 | 50,026 | 30.1% | |
No. of employees | `000 | 2.3 | 4.3 | 53.9% | |
Total wages/salary | Rs m | 1,471 | 3,140 | 46.8% | |
Avg. sales/employee | Rs Th | 1,973.6 | 4,027.5 | 49.0% | |
Avg. wages/employee | Rs Th | 635.6 | 731.4 | 86.9% | |
Avg. net profit/employee | Rs Th | 176.8 | -1,014.8 | -17.4% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 4,567 | 17,290 | 26.4% | |
Other income | Rs m | 45 | 121 | 37.0% | |
Total revenues | Rs m | 4,612 | 17,411 | 26.5% | |
Gross profit | Rs m | 2,030 | -2,996 | -67.7% | |
Depreciation | Rs m | 540 | 746 | 72.4% | |
Interest | Rs m | 1,048 | 468 | 223.8% | |
Profit before tax | Rs m | 486 | -4,090 | -11.9% | |
Minority Interest | Rs m | 0 | -11 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 77 | 256 | 30.2% | |
Profit after tax | Rs m | 409 | -4,357 | -9.4% | |
Gross profit margin | % | 44.4 | -17.3 | -256.5% | |
Effective tax rate | % | 15.9 | -6.2 | -253.8% | |
Net profit margin | % | 9.0 | -25.2 | -35.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 2,415 | 12,664 | 19.1% | |
Current liabilities | Rs m | 9,077 | 7,125 | 127.4% | |
Net working cap to sales | % | -145.9 | 32.0 | -455.4% | |
Current ratio | x | 0.3 | 1.8 | 15.0% | |
Inventory Days | Days | 65 | 111 | 58.7% | |
Debtors Days | Days | 71 | 124 | 57.2% | |
Net fixed assets | Rs m | 8,333 | 7,382 | 112.9% | |
Share capital | Rs m | 61 | 80 | 76.4% | |
Net worth | Rs m | 3,504 | 13,571 | 25.8% | |
Long term debt | Rs m | 461 | 4,769 | 9.7% | |
Total assets | Rs m | 13,755 | 25,636 | 53.7% | |
Interest coverage | x | 1.5 | -7.7 | -18.9% | |
Debt to equity ratio | x | 0.1 | 0.4 | 37.5% | |
Sales to assets ratio | x | 0.3 | 0.7 | 49.2% | |
Return on assets | % | 10.6 | -15.2 | -69.9% | |
Return on equity | % | 11.7 | -32.1 | -36.4% | |
Return on capital | % | 38.7 | -19.8 | -195.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,049 | 1,476 | 71.1% | |
From Investments | Rs m | -54 | -453 | 11.8% | |
From Financial Activity | Rs m | -1,011 | 4,328 | -23.4% | |
Net Cashflow | Rs m | -20 | 5,351 | -0.4% |
Compare PANACEA BIOTECH With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare PANACEA BIOTECH With: UNICHEM LAB PFIZER ABBOTT INDIA STERLING BIOTECH AJANTA PHARMA
The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.
Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
An Indian company founded three decades ago in a garage caught my attention...
In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.
More